ARTICLE | Preclinical News
UCL, Autolus develop CARs against T cell malignancies that partially preserve normal T cells
November 13, 2017 7:51 PM UTC
A Nature Medicine study published Monday describes a chimeric antigen receptor (CAR)-based strategy to target T cell malignancies without wiping out normal T cells. Autolus Ltd. (London, U.K.) licensed the technology from University College London.
CAR T cells against B cell malignancies deplete both cancerous and normal B cells, which is considered a tolerable side effect. In contrast, complete T cell depletion causes unacceptable immunosuppression, which has limited development of T cell-targeted CAR therapies...
BCIQ Target Profiles